These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 2702012)

  • 21. The drug safety review process.
    Somberg J
    Am J Ther; 2007; 14(2):119. PubMed ID: 17414577
    [No Abstract]   [Full Text] [Related]  

  • 22. [When can the cases of toxic or adverse effects of drugs be rejected? 80 cases].
    Lagier G; Castot A; Sabouraud S; de Cremoux P; Efthymiou ML
    Therapie; 1990; 45(5):435-6. PubMed ID: 2260040
    [No Abstract]   [Full Text] [Related]  

  • 23. Rhode Island physicians' recognition and reporting of adverse drug reactions.
    Scott HD; Rosenbaum SE; Waters WJ; Colt AM; Andrews LG; Juergens JP; Faich GA
    R I Med J (1976); 1987 Jul; 70(7):311-6. PubMed ID: 3476980
    [No Abstract]   [Full Text] [Related]  

  • 24. European commission consultation on pharmacovigilance.
    Waller P; Beard K; Egberts T; Evans S; Hallas J; Hasford J; Laporte JR; Moore N; Shakir S; Sturkenboom M
    Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):108-9. PubMed ID: 18058839
    [No Abstract]   [Full Text] [Related]  

  • 25. [Mandatory report of adverse effects of drugs: has the order modified the spontaneous notification?].
    Haramburu F; Pere JC; Begaud B; Albin H
    Therapie; 1988; 43(6):493-6. PubMed ID: 3227516
    [No Abstract]   [Full Text] [Related]  

  • 26. [Computerized detection of new adverse effects in drug surveillance. A proposal for the periodic use of the French data bank].
    Pham E; Ventre JJ; Saddier P; Descotes J; Evreux JC
    Therapie; 1988 May; 43(3):235-7. PubMed ID: 3420571
    [No Abstract]   [Full Text] [Related]  

  • 27. Provision of information on regulatory authorities' websites.
    Vitry A; Lexchin J; Sasich L; Dupin-Spriet T; Reed T; Bertele V; Garattini S; Toop L; Hurley E
    Intern Med J; 2008 Jul; 38(7):559-67. PubMed ID: 18336542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Contributing to drug safety.
    Johnson JM
    Am J Hosp Pharm; 1990 Jun; 47(6):1280. PubMed ID: 2368721
    [No Abstract]   [Full Text] [Related]  

  • 29. [Pharmaco-morbidity linking: a potential instrument for post-marketing surveillance].
    Stricker BH; Herings RM; Bakker A; Valkenburg HA; Sturmans F
    Ned Tijdschr Geneeskd; 1990 Sep; 134(39):1886-9. PubMed ID: 2215766
    [No Abstract]   [Full Text] [Related]  

  • 30. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 31. "Black box" 101: How the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk.
    Murphy S; Roberts R
    J Allergy Clin Immunol; 2006 Jan; 117(1):34-9. PubMed ID: 16387581
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Post marketing surveillance of new drugs. Patient safety in the hands of GPs.
    Marley JE
    Aust Fam Physician; 1989 Sep; 18(9):1133-5. PubMed ID: 2590077
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Methods for studying the adverse effects of drugs. I. Comparison of imputability methods: modelling and methodology].
    Péré JC; Begaud B; Haramburu F; Albin H
    Therapie; 1984; 39(3):279-89. PubMed ID: 6463953
    [No Abstract]   [Full Text] [Related]  

  • 35. Adverse reaction assessment in Thailand.
    Sriwatanakul K; Pothisiri P
    Med Toxicol; 1986; 1 Suppl 1():105-9. PubMed ID: 3821423
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Statewide test of a new postmarketing drug surveillance system.
    Fisher S; Bryant SG; Solovitz BL; Kluge RM
    Tex Med; 1987 Aug; 83(8):59-62. PubMed ID: 3660262
    [No Abstract]   [Full Text] [Related]  

  • 37. [Comparative organization of drug monitoring in France and 7 European countries].
    Vaissere J; de Cremiers F; Auriche M; Juillet Y
    Therapie; 1986; 41(5):369-74. PubMed ID: 3810527
    [No Abstract]   [Full Text] [Related]  

  • 38. An underrecognized challenge in evaluating postmarketing drug safety.
    Roden DM
    Circulation; 2005 Jan; 111(3):246-8. PubMed ID: 15668350
    [No Abstract]   [Full Text] [Related]  

  • 39. Food and Drug Administration monitoring of adverse drug reactions.
    Sills JM; Tanner LA; Milstien JB
    Am J Hosp Pharm; 1986 Nov; 43(11):2764-70. PubMed ID: 3799612
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Research methods in drug surveillance.
    Engel RR; Grohmann R; Rüther E; Hippius H
    Pharmacopsychiatry; 2004 Mar; 37 Suppl 1():S12-5. PubMed ID: 15052510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.